Prophylaxis Against Plasmodium Falciparum Malaria Clinical Trial
Official title:
Ph-1 Double-Blind Randomized Control Study-Evaluate Safety & Immunogenicity of Wanxing Bio-Pharmaceuticals AMA-1/MSP-1 Recombinant Malaria Vaccine (PfCP-2.9) Adj. w/ Montanide ISA 720 Compared to Montanide ISA 720 Alone in Adult Volunteers
Shanghai Wanxing Bio-Pharmaceuticals is currently evaluating one malaria vaccine candidate,
PfCP2.9 adjuvanted with Montanide ISA 720. This trial is designed to test the safety and
immunogenicity of 3 doses and 2 vaccination schedules.
This blood stage candidate malaria vaccine is being developed for the routine immunization
of infants and children living in malaria-endemic areas.
This is a double blind, randomized, controlled Phase I study of PfCp2.9, an experimental
malaria vaccine candidate, adjuvanted with Montanide ISA 720.
The primary objective of this study is to assess the safety and reactogenicity of the
vaccine in healthy Chinese adult volunteers.
;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention